Irene Pericot-Valverde, Moonseong Heo, Erik G Ortiz, Ashley C King, Angelica Perez, Laksika B Sivaraj, Snehal S Lopes, Kaileigh A Byrne, Alain H Litwin
{"title":"阿片类药物使用障碍患者计算机行为治疗和康复指导相结合的综合干预的随机试点试验:克服研究。","authors":"Irene Pericot-Valverde, Moonseong Heo, Erik G Ortiz, Ashley C King, Angelica Perez, Laksika B Sivaraj, Snehal S Lopes, Kaileigh A Byrne, Alain H Litwin","doi":"10.1097/ADM.0000000000001578","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>People with opioid use disorder (OUD) often exhibit high rates of nonprescribed drug use and low retention on buprenorphine. This study tested the feasibility, acceptability, and preliminary efficacy of an intervention combining peer recovery coaching and CBT4CBT-buprenorphine (CBT4CBT+RC) to reduce nonprescribed drug use and increase buprenorphine retention.</p><p><strong>Methods: </strong>A randomized trial conducted from December 15, 2020, to November 24, 2021, compared an 8-week CBT4CBT+RC intervention to treatment as usual (TAU). Outcomes included feasibility (recruitment, treatment initiation, and completion), acceptability (of CBT4CBT, recovery coaching, and integrated intervention), and preliminary efficacy (saliva toxicology and buprenorphine retention during treatment and at 1- and 3-mo follow-ups). Participants (N=38) had been receiving buprenorphine for an average of 270.1 days (SD=444.0) and reported recent nonprescribed drug use.</p><p><strong>Results: </strong>Recruitment feasibility was 33.7%. Of the 19 participants assigned to CBT4CBT+RC, 94.7% met with a coach, and 52.6% initiated CBT4CBT. The average number of modules completed was 6.0 (299.7 min). Satisfaction with the intervention, coach, and CBT4CBT-buprenorphine was high (M≥4.9). Drug use was significantly lower in the CBT4CBT+RC group compared with TAU during treatment (35% vs. 69%, P=0.03), at 1 month (34% vs. 69%, P=0.009), and at 3 months (0% vs. 88%, P<0.001). Retention and opioid-positive tests did not differ between groups.</p><p><strong>Conclusions: </strong>The CBT4CBT+RC condition resulted in lower rates of saliva toxicology positive for drug use during treatment and follow-ups, but showed comparable buprenorphine retention rates to TAU. These findings provide promising support for the potential of CBT4CBT+RC to reduce drug use among individuals with OUD.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Randomized Pilot Trial of an Integrated Intervention Combining Computerized Behavioral Therapy and Recovery Coaching for People With Opioid Use Disorder: The OVERCOME Study.\",\"authors\":\"Irene Pericot-Valverde, Moonseong Heo, Erik G Ortiz, Ashley C King, Angelica Perez, Laksika B Sivaraj, Snehal S Lopes, Kaileigh A Byrne, Alain H Litwin\",\"doi\":\"10.1097/ADM.0000000000001578\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>People with opioid use disorder (OUD) often exhibit high rates of nonprescribed drug use and low retention on buprenorphine. This study tested the feasibility, acceptability, and preliminary efficacy of an intervention combining peer recovery coaching and CBT4CBT-buprenorphine (CBT4CBT+RC) to reduce nonprescribed drug use and increase buprenorphine retention.</p><p><strong>Methods: </strong>A randomized trial conducted from December 15, 2020, to November 24, 2021, compared an 8-week CBT4CBT+RC intervention to treatment as usual (TAU). Outcomes included feasibility (recruitment, treatment initiation, and completion), acceptability (of CBT4CBT, recovery coaching, and integrated intervention), and preliminary efficacy (saliva toxicology and buprenorphine retention during treatment and at 1- and 3-mo follow-ups). Participants (N=38) had been receiving buprenorphine for an average of 270.1 days (SD=444.0) and reported recent nonprescribed drug use.</p><p><strong>Results: </strong>Recruitment feasibility was 33.7%. Of the 19 participants assigned to CBT4CBT+RC, 94.7% met with a coach, and 52.6% initiated CBT4CBT. The average number of modules completed was 6.0 (299.7 min). Satisfaction with the intervention, coach, and CBT4CBT-buprenorphine was high (M≥4.9). Drug use was significantly lower in the CBT4CBT+RC group compared with TAU during treatment (35% vs. 69%, P=0.03), at 1 month (34% vs. 69%, P=0.009), and at 3 months (0% vs. 88%, P<0.001). Retention and opioid-positive tests did not differ between groups.</p><p><strong>Conclusions: </strong>The CBT4CBT+RC condition resulted in lower rates of saliva toxicology positive for drug use during treatment and follow-ups, but showed comparable buprenorphine retention rates to TAU. These findings provide promising support for the potential of CBT4CBT+RC to reduce drug use among individuals with OUD.</p>\",\"PeriodicalId\":14744,\"journal\":{\"name\":\"Journal of Addiction Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Addiction Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/ADM.0000000000001578\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addiction Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ADM.0000000000001578","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
A Randomized Pilot Trial of an Integrated Intervention Combining Computerized Behavioral Therapy and Recovery Coaching for People With Opioid Use Disorder: The OVERCOME Study.
Background: People with opioid use disorder (OUD) often exhibit high rates of nonprescribed drug use and low retention on buprenorphine. This study tested the feasibility, acceptability, and preliminary efficacy of an intervention combining peer recovery coaching and CBT4CBT-buprenorphine (CBT4CBT+RC) to reduce nonprescribed drug use and increase buprenorphine retention.
Methods: A randomized trial conducted from December 15, 2020, to November 24, 2021, compared an 8-week CBT4CBT+RC intervention to treatment as usual (TAU). Outcomes included feasibility (recruitment, treatment initiation, and completion), acceptability (of CBT4CBT, recovery coaching, and integrated intervention), and preliminary efficacy (saliva toxicology and buprenorphine retention during treatment and at 1- and 3-mo follow-ups). Participants (N=38) had been receiving buprenorphine for an average of 270.1 days (SD=444.0) and reported recent nonprescribed drug use.
Results: Recruitment feasibility was 33.7%. Of the 19 participants assigned to CBT4CBT+RC, 94.7% met with a coach, and 52.6% initiated CBT4CBT. The average number of modules completed was 6.0 (299.7 min). Satisfaction with the intervention, coach, and CBT4CBT-buprenorphine was high (M≥4.9). Drug use was significantly lower in the CBT4CBT+RC group compared with TAU during treatment (35% vs. 69%, P=0.03), at 1 month (34% vs. 69%, P=0.009), and at 3 months (0% vs. 88%, P<0.001). Retention and opioid-positive tests did not differ between groups.
Conclusions: The CBT4CBT+RC condition resulted in lower rates of saliva toxicology positive for drug use during treatment and follow-ups, but showed comparable buprenorphine retention rates to TAU. These findings provide promising support for the potential of CBT4CBT+RC to reduce drug use among individuals with OUD.
期刊介绍:
The mission of Journal of Addiction Medicine, the official peer-reviewed journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical sub-specialty.
Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics including:
•addiction and substance use in pregnancy
•adolescent addiction and at-risk use
•the drug-exposed neonate
•pharmacology
•all psychoactive substances relevant to addiction, including alcohol, nicotine, caffeine, marijuana, opioids, stimulants and other prescription and illicit substances
•diagnosis
•neuroimaging techniques
•treatment of special populations
•treatment, early intervention and prevention of alcohol and drug use disorders
•methodological issues in addiction research
•pain and addiction, prescription drug use disorder
•co-occurring addiction, medical and psychiatric disorders
•pathological gambling disorder, sexual and other behavioral addictions
•pathophysiology of addiction
•behavioral and pharmacological treatments
•issues in graduate medical education
•recovery
•health services delivery
•ethical, legal and liability issues in addiction medicine practice
•drug testing
•self- and mutual-help.